No CrossRef data available.
Article contents
Dopamine stabilizes milrinone-induced changes in heart rate and arterial pressure during anaesthesia with isoflurane
Published online by Cambridge University Press: 02 June 2005
Abstract
Summary
Background and objective: Phosphodiesterase-III inhibitors and dobutamine effectively improve cardiac function in patients with cardiac failure, but they are limited by possible hypotensive effects. We tested the hypothesis that dopamine contributes to stabilizing milrinone-induced haemodynamic changes.
Methods: Nine patients undergoing major surgery were anaesthetized using nitrous oxide and oxygen supplemented with isoflurane 1–2%. After baseline haemodynamics were recorded, milrinone (25 or 50 μg kg−1) was administered over 10 min, followed by a continuous infusion (0.5 μg kg−1 min−1). The second set of haemodynamic values was measured 50 min after beginning the continuous infusion of milrinone. Dopamine (4 μg kg−1 min−1) was then administered with milrinone.
Results: Milrinone significantly increased the heart rate from 81 ± 8 to 102 ± 16 beats min−1, but it decreased the mean arterial pressure from 83 ± 10 to 66 ± 10 mmHg and systemic vascular resistance (P < 0.05 for each). The pulmonary capillary wedge pressure, cardiac index and pulmonary vascular resistance did not change significantly. The addition of dopamine to the milrinone infusion significantly decreased the heart rate (94 ± 12 beats min−1) and increased the mean arterial pressure (82 ± 11 mmHg). Dopamine and milrinone, but not milrinone alone, significantly increased the cardiac index and the rate–pressure product.
Conclusions: The combination regimen of milrinone and dopamine improved cardiac function, and changes in heart rate and mean arterial pressure induced by milrinone were attenuated by dopamine. The results suggest that a combination regimen of milrinone and dopamine rather than milrinone alone should be used to maintain arterial pressure.
Keywords
- Type
- Original Article
- Information
- Copyright
- 2003 European Society of Anaesthesiology
References
Monrad ES, Baim DS, Smith HS, et al. Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. Circulation 1985; 71: 972–979.Google Scholar
Mitrovic V, Stohring R, Schlepper M. The use of intravenous milrinone in chronic symptomatic ischemic heart disease. Am Heart J 1991; 121: 1983–1994.Google Scholar
Dubois-Rande JL, Duval-Mooulin AM, Saal JP, et al. Physiologic assessment of milrinone therapy in severe heart failure patients. J Cardiovasc Pharmacol 1991; 17: 941–948.Google Scholar
Klocke RK, Mager G, Kux A, et al. Effects of twenty-four hour milrinone infusion in patients with severe heart failure and cardiogenic shock as a function of the hemodynamic initial condition. Am Heart J 1991; 121: l965–1973.Google Scholar
Sidi A, Pool JM, Rush W. Early administration of amrinone does not impair regional metabolism of O2 or lactate and, by improving myocardial performance, preserves myocardial blood flow in the ischemic canine heart. Anesth Analg 1993; 79: 1201–1212.Google Scholar
Uretsky BF, Lawless CE, Verbalis JG, et al. Combination therapy with dobutamine and amrinone in severe heart failure improved hemodynamics and increased activation of the rennin–angiotensin system with combined intravenous therapy. Chest 1987; 92: 657–662.Google Scholar
Hardy JF, Searle N, Roy M, Perrault J. Amrinone, in combination with norepinephrine, is an effective first-line drug for difficult separation from cardiopulmonary bypass. Can J Anaesth 1993; 40: 495–501.Google Scholar
Meissner A, Herrmann G, Gerdesmeyer L, Simon R. Additive effects of milrinone and dobutamine in severe heart failure. Z Kardiol 1992; 81: 266–271.Google Scholar
Orime Y, Shiono M, Hata H, et al. Effects of concomitant usage of milrinone and catecholamine for weaning from cardiopulmonary bypass. Jpn J Thoracic Cardiovasc Surg 1998; 46: 803–809.Google Scholar
Sha K, Shimokawa M, Ishimaru K, et al. Differences in hemodynamic effects of amrinone, milrinone, and olprinone after cardiopulmonary bypass in valvular cardiac surgery. Masui (Jpn J Anesthesiology) 2000; 49: 981–986.Google Scholar
Yeh BK, McNay JL, Goldberg LI. Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific dopamine receptor. J Pharmacol Exp Ther 1969; 168: 803–809.Google Scholar
Murphy MB, Elliott WJ. Dopamine and dopamine receptor agonists in cardiovascular therapy. Crit Care Med 1990; 18: S14–S18.Google Scholar
Okuno Y, Mashimo T, Takashina M, et al. Hemodynamic effects of amrinone combined with dopamine in patients undergoing living renal transplantation. Masui 1997; 46: 87–94.Google Scholar
Wright EM, Sherry KM. Clinical and haemodynamic effects of milrinone in the treatment of low cardiac output after cardiac surgery. Br J Anaesth 1995; 67: 585–590.Google Scholar
Hert SG, Moens MM, Jorens PG, et al. Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. J Cardiothoracic Vasc Anesth 1995; 5: 264–271.Google Scholar
McNay JL, Goldberg LI. Comparison of the effects of dopamine, isoproterenol, norepinephrine, and bradykinin on canine renal and femoral blood flow. J Pharmacol Exp Ther 1966; 151: 23–31.Google Scholar
Olsen KH, Kluger J, Fieldman A. Combination high dose amrinone and dopamine in the management of moribund cardiogenic shock after open heart surgery. Chest 1988; 94: 500–506.Google Scholar
Jones JL. Gengo PJ, Dodan JR, Hellyer PW. Amrinone combined with dobutamine improves hemodynamics and oxygen delivery without downregulation of cardiac beta-adrenergic receptor density in porcine endotoxemia. Shock 1995; 3: 224–234.Google Scholar
Hirabayashi Y, Igarashi T, Saitoh K, et al. Comparison of the effects of amrinone, milrinone and olprinone in reversing bupivacaine-induced cardiovascular depression. Acta Anaesth Scand 2000; 44: 1128–1133.Google Scholar
Carl VL, Paul TH, Patricia HRN, Charles AB, Pichard PL. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1978; 58: 466–475.Google Scholar
Minatoguchi S, Majewski H. Milrinone inhibits sympathetic-mediated tachycardia by a postjunctional action independent of cyclic AMP. J Cardiovasc Pharmacol 1991; 18: 127–136.Google Scholar
Butterworth JF, Hines RL, Royster RL, James RL. A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. Anesth Analg 1995; 81: 783–792.Google Scholar
Ktaja J. Thoracolumbar epidural anaesthesia and isoflurane to prevent hypertension and tachycardia in patients undergoing abdominal aortic surgery. Eur J Anaesth 1991; 8: 427–436.Google Scholar
Tanaka S, Tsuchida H, Namba H, Namiki A. Clonidine and lidocaine inhibition of isoflurane-induced tachycardia in humans. Anesthesiology 1994; 81: 1341–1349.Google Scholar
Miller RR, Palmo AR, Brandon TA, Hartley CJ, Quinones MA. Combined vasodilator and inotropic therapy of heat failure: experimental and clinical concepts. Am Heart J 1981; 102: 500–508.Google Scholar